CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Tissue plasminogen activatorWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug2447 Ringer solution Wiki 1.00
drug313 Azithromycin Wiki 0.17
drug1284 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.10
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS): A Multicentral Randomized Trial (AtTAC-trial)

At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness. There is hypothesis that in predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and by microvascular pulmonary thrombosis. The investigators suggest that thrombolytic therapy may be beneficial when compared to standard care in patients with SARS-CoV-2 and severe respiratory failure.

NCT04453371 Acute Respiratory Distress Syndrome Drug: Tissue plasminogen activator Drug: Ringer solution
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Measure: P/F (PaO2/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV.

Time: Each 6 hours during first 3 days after the end of thrombolysis procedure.

Secondary Outcomes

Description: Calculated as 28 days - number of days when patient receive any kind of ventilatory support (MV + SV + NIV).

Measure: Ventilator-free time (days free from MV) for 28 days of observation.

Time: 28 days

Other Outcomes

Measure: Mortality in 28 days and 1 year after randomization despite of the reason.

Time: 28 days, 1 year after randomization

Description: Number of days when patient was in ICU

Measure: Length of stay in the ICU

Time: 28 days

Description: Number of days when patient was in hospital

Measure: Length of stay in hospital

Time: 28 days

Measure: The time needed for "improvement of 2 points" according to WHO "Ordinal Scale for Clinical Improvement"

Time: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month

Measure: Chest radiographs on a daily basis and define barotrauma as the presence of new pneumothorax, pneumomediastinum, pneumoperitoneum, or subcutaneous emphysema.

Time: Daily up to extubation than once a week/or on attending intensivist's discretion up to 1 month

Measure: Blood Pressure in millimetres of mercury

Time: Each 4 hours during first 2 weeks after the end of thrombolysis procedure.

Measure: Heart Rate in beats per minute

Time: Each 4 hours during first 2 weeks after the end of thrombolysis procedure.

Measure: Blood Oxygen Saturation

Time: Each 4 hours during first 2 weeks after the end of thrombolysis procedure.

Measure: ECG Q-wave

Time: Each 24 hours during first 2 weeks after the end of thrombolysis procedure.

Measure: ECG ST-segment

Time: Each 24 hours during first 2 weeks after the end of thrombolysis procedure.

No related HPO nodes (Using clinical trials)